	US 12,213,985 B2
	Oral cannabinoid formulations
Harshit Shah, Cambridge (GB)
Assigned to Jazz Pharmaceuticals Research UK Limited, Sittingbourne (GB)
Filed by Jazz Pharmaceuticals Research UK Limited, Sittingbourne (GB)
Filed on Mar. 8, 2022, as Appl. No. 17/689,245.
Application 17/689,245 is a division of application No. 16/314,569, granted, now 11,291,631, previously published as PCT/GB2017/051914, filed on Jun. 29, 2017.
Claims priority of application No. 1611547 (EP), filed on Jul. 1, 2016.
Prior Publication US 2022/0362149 A1, Nov. 17, 2022
Int. Cl. A61K 31/00 (2006.01); A61K 9/00 (2006.01); A61K 9/08 (2006.01); A61K 31/05 (2006.01); A61K 47/10 (2017.01); A61K 47/14 (2017.01); A61K 47/44 (2017.01); A61P 25/08 (2006.01)

CPC A61K 31/658 (2023.05) [A61K 9/0095 (2013.01); A61K 9/08 (2013.01); A61K 31/05 (2013.01); A61K 47/10 (2013.01); A61K 47/14 (2013.01); A61K 47/44 (2013.01); A61P 25/08 (2018.01)]

27 Claims

1. A method of treating a disease or disorder, the method comprising orally administering to a subject in need thereof a therapeutically effective amount of a pharmaceutical formulation comprising:

cannabidiol (CBD);

a lipid solvent;

an ultrahigh potency sweetener; and

ethanol, wherein ethanol has a concentration of less than about 3% v/v, and

wherein the disease or disorder is epilepsy or a syndrome associated therewith, schizophrenia, tuberous sclerosis complex, brain tumors, neuropathic pain, cannabis use disorder. post-traumatic stress disorder, anxiety, early psychosis, Alzheimer's Disease, or autism.